Lavelle Erin 4
4 · Neoleukin Therapeutics, Inc. · Filed May 16, 2022
Insider Transaction Report
Form 4
Lavelle Erin
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-12+25,000→ 25,000 totalExercise: $1.07Exp: 2032-05-11→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.